Evgen Pharma in dispute with partner

Sulforaphane-based medicines developer Evgen Pharma (LON: EVG) has issued a notice of dispute with Stalicla its partner in autism spectrum disorder and other neurodevelopmental disorders. The share price has fallen by more than one-quarter to 1.1p, which is a new all-time low.

AIM-quoted Evgen Pharma licenced the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia. The initial payment was $500,000 with a further $500,000 due on completion of the human volunteer phase 1 study. That was completed in August 2023. The dispute resolution process has been started so that the payment is received.

- Advertisement -

In January, Stalicla raised $17.4m in a Series B fundraising and a credit facility.

Evgen Pharma had a cash of £3.7m at the end of September 2023. That was after a cash outflow from operations of £1.3m.

- Advertisement -

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This

Tagdiv Cloud library - template content.